Endocrine Abstracts

Objective: Graves’ orbitopathy (GO) is an autoimmune disease that affects about 25% of the patients with Graves’ disease. The thyrotropin receptor (TSHR) is the main autoantigen of GO. Somatostatin receptors (SSR) are expressed by orbital fibroblasts (OB) of GO patients. Pasireotide (SOM230) is a somatostatin analog that has a great affinity for the type 1 and type 5 SSRs and inhibits both orbital human lymphocyte and OB proliferation in vitro. Therefore it is intere...